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therefore careful selection of the appropriate assay
is an important clinical and research consideration.
Benjamin M. Scirica, M.D., M.P.H.
Eugene Braunwald, M.D.
Deepak L. Bhatt, M.D., M.P.H.

of

m e dic i n e

with type 2 diabetes and known congestive heart failure treated
with saxagliptin: analyses of the SAVOR-TIMI 53 Study. Circulation 2013;128:A17503. abstract.

heart failure, we have initiated analyses of heartfailure outcomes in our trial. In patients with
type 2 diabetes and a recent acute coronary syndrome, including patients with a history of heart
failure and those with elevated baseline levels of
N-terminal pro–brain natriuretic peptide, cardiovascular outcomes inclusive of hospitalization for
heart failure were not increased with alogliptin
as compared with placebo. In addition, alogliptin
neither induced new-onset heart failure nor
worsened heart-failure outcomes in patients with
a history of heart failure before randomization.
We will continue to analyze results related to this
important question in our trial.
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Preparing for Responsible Sharing of Clinical Trial Data
To the Editor: Mello et al. (Oct. 24 issue)1 identify ensuring the responsible use of data as a key
aspect of any system for expanded access to participant-level data. In their careful framework for
considering the legal, ethical, and policy implications of such sharing, however, they omit a
powerful mechanism to meet this aim. Open
computer code facilitates replication, which both
advances knowledge2 and holds powerful interests accountable.3
Regardless of which of the four proposed
models are adopted, data-use agreements should
require data requesters to publish their computer
code alongside any analysis. The program should
be complete, in that it takes as its input the provided trial data and finishes by providing every
table, figure, and summary statistic reported in
the final paper.
Just as proposals for an increase in the level
of shared clinical trial data use openness as a
mechanism to hold data generators accountable,
openness can hold data requesters accountable.
If scientists can make progress in ensuring the
replicability of studies that include the use of
484
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genetically modified mice,4 surely the far easier
task of ensuring replicable reanalyses can be
achieved.
Ari B. Friedman, M.S.
Leonard Davis Institute of Health Economics
Philadelphia, PA
arib@alumni.upenn.edu
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To the Editor: Mello and colleagues outline the
potential benefits and risks of participant-level
data sharing. They highlight technical and ethical concerns as sponsors and investigators move
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these initiatives forward. However, insofar as innovations overcome important limitations such
as intellectual property and privacy, two points
remain relevant.
First, implementing responsible participantlevel data sharing is a moral imperative to accelerate discovery with limited resources and to
address the ominous quality of scientific output.
Current siloed and fragmented science fails to
answer important questions in an increasingly
complex world.1 Conversely, participant-level data
sharing shifts the paradigm to collaboration,
which enables the pooling of skills, insights, and
resources from different teams.2
Second, concurrently with this wave of data
availability, computational tools can now tackle
big data opportunities. It is possible to manage
large-scale data sets, reformat them to link and
integrate, and construct analytic algorithms in
an effective and timely fashion.3 A perfect storm
is exposing a large volume of data to new tools,

paving the way to groundbreaking collaboration
across networks to increase productivity and
boost the quality of medical science.
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Access to Patient-Level Trial Data
To the Editor: The Chief Medical Officers
Roundtable (CMOR), of which we are members,
welcomes the Perspective article by Eichler et al.
(Oct. 24 issue),1 who are representatives of the
European Medicines Agency (EMA), on access to
patient-level trial data. CMOR formulates positions on medical topics, and its members include
chief medical officers of major biopharmaceutical companies. CMOR supports a transparent,
harmonized process for access to patient-level
clinical trial data.
Any approach to clinical trial data sharing
must be in the interest of patients. Data sharing
should be based on two tenets. First, principles
should apply uniformly to all who generate
clinical trial data — industry, academia, regulators, health systems, foundations, and others.
There will be little benefit to patients if access
does not occur across sectors. Second, the responsible release of data requires input from
independent experts and agreements to respect
confidentiality, promote scientific excellence, refrain from misleading conclusions (which can
harm patients if they discontinue beneficial treatment),2 and safeguard future innovation by retaining incentives for investigators.
Access should be determined after the subn engl j med 370;5

mission of a proposal to a panel that includes
independent experts. Evaluation should be based
on scientific merit, relevance, researcher qualifications, potential conflicts of interest, and plans
for dissemination of findings after peer review.
To this end, the CMOR supports the consensus
study launched by the Institute of Medicine. It is,
to our knowledge, the only broadly inclusive
initiative and has the international participation
of academia, industry, the National Institutes of
Health, the Food and Drug Administration, the
EMA, journals, patient organizations, foundations, and others.2
Contrary to the assertion by Eichler et al. that
industry opposes the sharing of patient-level data,
many companies are creating processes like those
mentioned above.2 Industry already shares results through ClinicalTrials.gov, public websites,
and scientific publications.3
Furthermore, the European Federation of
Pharmaceutical Industries and Associations and
the Pharmaceutical Research and Manufacturers
of America have moved beyond the status quo in
adopting the Principles for Responsible Clinical
Trial Data Sharing, which will be implemented
in January 2014 and include the following major
points.4 First, patient- and study-level clinical
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